TREE NEWS update: Sanofi and its US partner Regeneron said Thursday they will expand their collaboration to jointly develop four new drugs, in a deal worth up to $8 billion including milestone payments of as much as $7 billion. Sanofi will pay Regeneron a $1 billion upfront payment, with further payments tied to development, regulatory and commercial milestones. Sanofi shares rose 2% in early European trading.
Sanofi, Regeneron Expand Partnership in $8B Deal
AI take
The structure matters more than the headline number: the bulk of the consideration is milestone-linked, so the real commitment is the upfront cash, with the rest contingent on programs that have not yet cleared development or regulatory hurdles. The muted share reaction suggests the market read this as a pipeline top-up rather than a re-rating event. Whether the four programs advance on schedule, and how much of the milestone pool is actually triggered, is the open question.
Generated by AI for reference only.
Share on WeChat
Open WeChat → Scan → then tap "…" to send to a chat or Moments.
Tap "…" in the top-right corner to send to a chat or share to Moments.
Related News
4m ago
Traders Cut ECB Rate-Cut Bets, Now Price Three Hikes by End-2027
6m ago
EU in Talks With Member States on Emergency Diesel Reserves
24m ago
Geely September Sales Rise 7% to 292,168 Vehicles as Zeekr Doubles
25m ago
Hedge Funds Double Down on Shorting Euro as French Risks Mount
32m ago
EU Seeks Unified Position as US Urges Europe to Release Diesel Reserves
38m ago
2026 Nobel Prizes to Be Announced October 5-12